PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16129692-4 2005 Epidermal growth factor receptor Tyr phosphorylation was unchanged following Aalpha knockdown, suggesting that chronic Akt and ERK hyperphosphorylation leads to compensatory down-regulation of signaling molecules upstream of Ras and blunted growth factor responses. Tyrosine 33-36 epidermal growth factor receptor Rattus norvegicus 0-32 16039106-7 2006 In vitro studies, cigarette smoke solution was found to increase TNFalpha secretion, and EGFR-specific tyrosine phosphorylation, and to elevate MUC5AC production. Tyrosine 103-111 epidermal growth factor receptor Rattus norvegicus 89-93 16317705-8 2005 Treatment of rat hepatocytes with PTX abolished TDCA-induced tyrosine phosphorylation of ERBB1. Tyrosine 61-69 epidermal growth factor receptor Rattus norvegicus 89-94 15652497-3 2005 Inhibition of Cdc25 phosphatases in rat liver epithelial cells employing a 1,4-naphthoquinone-based inhibitor, NSC95397, induced cell cycle arrest, tyrosine phosphorylation of the epidermal growth factor receptor (EGFR), and activation of extracellular signal-regulated kinases ERK-1 and -2. Tyrosine 148-156 epidermal growth factor receptor Rattus norvegicus 180-212 15917250-10 2005 Activated EGFR then triggered an AG1478-sensitive CD95-tyrosine phosphorylation, which was a signal for membrane targeting of the EGFR/CD95 complex, subsequent recruitment of Fas-associated death domain and caspase 8, and apoptosis induction. Tyrosine 55-63 epidermal growth factor receptor Rattus norvegicus 10-14 15917250-10 2005 Activated EGFR then triggered an AG1478-sensitive CD95-tyrosine phosphorylation, which was a signal for membrane targeting of the EGFR/CD95 complex, subsequent recruitment of Fas-associated death domain and caspase 8, and apoptosis induction. Tyrosine 55-63 epidermal growth factor receptor Rattus norvegicus 130-134 16164960-6 2005 Both dusts and a citrate extract caused phosphorylation of the EGF receptor on tyrosine 845, an indicator of Src activity. Tyrosine 79-87 epidermal growth factor receptor Rattus norvegicus 63-75 15905421-4 2005 This was prevented by selective inhibition of the intrinsic tyrosine kinase activity of the EGF-R by AG1478 [4-(3"-chloroanilino)-6,7-dimethoxy-quinazoline] and was reduced by inhibition of PKC and phosphoinositide 3-kinase. Tyrosine 60-68 epidermal growth factor receptor Rattus norvegicus 92-97 15358595-2 2005 ANG II induced a rapid and striking EGFR tyrosine phosphorylation, which was prevented by selective inhibitors of EGFR tyrosine kinase activity (e.g., AG-1478) or by broad-spectrum matrix metalloproteinase (MMP) inhibitor GM-6001. Tyrosine 41-49 epidermal growth factor receptor Rattus norvegicus 36-40 15358595-2 2005 ANG II induced a rapid and striking EGFR tyrosine phosphorylation, which was prevented by selective inhibitors of EGFR tyrosine kinase activity (e.g., AG-1478) or by broad-spectrum matrix metalloproteinase (MMP) inhibitor GM-6001. Tyrosine 41-49 epidermal growth factor receptor Rattus norvegicus 114-118 15465928-8 2005 Although Go6976 caused a significant increase in EGF-induced tyrosine phosphorylation of the EGF-R and subsequent ERK1/2 activation, it had no such effects on LPA-induced responses. Tyrosine 61-69 epidermal growth factor receptor Rattus norvegicus 93-98 15465928-10 2005 These data indicate that Go6976 potentiates agonist-induced ERK1/2 activation through stimulation of tyrosine phosphorylation of the EGF-R. Tyrosine 101-109 epidermal growth factor receptor Rattus norvegicus 133-138 14679192-1 2004 Epidermal growth factor receptor-dependent CD95-tyrosine phosphorylation was recently identified as an early step in apoptosis induction via the CD95 system (Reinehr, R., Schliess, F., and Haussinger, D. (2003) FASEB J. Tyrosine 48-56 epidermal growth factor receptor Rattus norvegicus 0-32 15563939-4 2004 In Fischer-344 rats, aging is associated with increased activation of EGFR in the colonic mucosa, as evidenced by 30-35% increase in the levels of tyrosine phosphorylated EGFR in the proximal and distal colon of aged (20-22 months old) than in young (4-6 months old) rats. Tyrosine 147-155 epidermal growth factor receptor Rattus norvegicus 70-74 15521021-1 2004 BACKGROUND AND AIMS: Hydrophobic bile acids induce CD95 (Fas, APO-1)-dependent hepatocyte apoptosis, which involves epidermal growth factor receptor (EGFR)-catalyzed CD95 tyrosine phosphorylation. Tyrosine 171-179 epidermal growth factor receptor Rattus norvegicus 116-148 15521021-1 2004 BACKGROUND AND AIMS: Hydrophobic bile acids induce CD95 (Fas, APO-1)-dependent hepatocyte apoptosis, which involves epidermal growth factor receptor (EGFR)-catalyzed CD95 tyrosine phosphorylation. Tyrosine 171-179 epidermal growth factor receptor Rattus norvegicus 150-154 15521021-5 2004 EGFR phosphorylation by TLCS involves tyrosines 845 and 1173 but not 1045. Tyrosine 38-47 epidermal growth factor receptor Rattus norvegicus 0-4 15521021-10 2004 CONCLUSIONS: The data identify the Src kinase Yes as an upstream target of proapoptotic bile acids, which triggers EGFR activation, subsequent CD95 tyrosine phosphorylation, and apoptosis. Tyrosine 148-156 epidermal growth factor receptor Rattus norvegicus 115-119 15039424-10 2004 When the hyperosmolarity-induced Yes-EGFR protein complex started to disappear after 30 min, an association between EGFR and CD95 became apparent, which was followed by CD95 tyrosine phosphorylation and activation. Tyrosine 174-182 epidermal growth factor receptor Rattus norvegicus 37-41 15039424-10 2004 When the hyperosmolarity-induced Yes-EGFR protein complex started to disappear after 30 min, an association between EGFR and CD95 became apparent, which was followed by CD95 tyrosine phosphorylation and activation. Tyrosine 174-182 epidermal growth factor receptor Rattus norvegicus 116-120 15039424-12 2004 EGFR knockdown had no effect on hyperosmotic Yes activation but prevented CD95 tyrosine phosphorylation, membrane targeting, and DISC formation. Tyrosine 79-87 epidermal growth factor receptor Rattus norvegicus 0-4 15044318-3 2004 We show that platelet-derived growth factor beta receptor (PDGFbetaR) and EGFR are tyrosine phosphorylated in response to S1P in rat aortic vascular smooth muscle cells (VSMCs). Tyrosine 83-91 epidermal growth factor receptor Rattus norvegicus 74-78 12949729-0 2003 Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation. Tyrosine 96-104 epidermal growth factor receptor Rattus norvegicus 48-80 14630916-6 2004 Bradykinin caused activation of p60Src and Src-dependent phosphorylation of the EGFR on Tyr-845 in lipid rafts, as well as recruitment of phospholipase C (PLC) gamma1 to the rafts. Tyrosine 88-91 epidermal growth factor receptor Rattus norvegicus 80-84 12949729-3 2003 RESULTS: Within 1 minute, the proapoptotic bile salts taurolithocholate-3-sulfate and glycochenodeoxycholate induced oxidative stress and EGF receptor (EGF-R) tyrosine phosphorylation followed by rapid c-Jun-N-terminal kinase (JNK) activation. Tyrosine 159-167 epidermal growth factor receptor Rattus norvegicus 138-157 12949729-4 2003 Thereafter, EGF-R associated with CD95 with subsequent CD95 tyrosine phosphorylation, CD95 membrane targeting, and death-inducing signal complex (DISC) formation. Tyrosine 60-68 epidermal growth factor receptor Rattus norvegicus 12-17 12586732-3 2003 After 30 min of hyperosmotic exposure EGFR associated with CD95 and CD95 became tyrosine phosphorylated. Tyrosine 80-88 epidermal growth factor receptor Rattus norvegicus 38-42 12949729-9 2003 CONCLUSIONS: Induction of apoptosis by hydrophobic bile salts involves EGF-R activation and EGF-R-dependent CD95 tyrosine phosphorylation, which triggers CD95 membrane targeting and Fas-associated death domain/caspase-8 recruitment. Tyrosine 113-121 epidermal growth factor receptor Rattus norvegicus 92-97 12586732-5 2003 Inhibition of EGFR tyrosine kinase activity prevented CD95 tyrosine phosphorylation and DISC formation but not hyperosmolarity-induced EGFR phosphorylation and EGFR association with CD95. Tyrosine 19-27 epidermal growth factor receptor Rattus norvegicus 14-18 12589790-0 2003 Protein kinase A mediates cAMP-induced tyrosine phosphorylation of the epidermal growth factor receptor. Tyrosine 39-47 epidermal growth factor receptor Rattus norvegicus 71-103 12388118-7 2003 Phenylephrine stimulated tyrosine phosphorylation of the EGFR, whereas carbachol stimulated p60(Src), and possibly Pyk2, to activate MAPK. Tyrosine 25-33 epidermal growth factor receptor Rattus norvegicus 57-61 12218049-2 2002 Here we show that an increase in the intracellular cAMP concentration induces tyrosine phosphorylation of two receptor tyrosine kinases, i.e. the epidermal growth factor (EGF) receptor and the high affinity receptor for nerve growth factor (NGF), also termed Trk(A). Tyrosine 78-86 epidermal growth factor receptor Rattus norvegicus 146-184 12218049-3 2002 cAMP-induced tyrosine phosphorylation of the EGF receptor is rapid and correlates with ERK1/2 activation. Tyrosine 13-21 epidermal growth factor receptor Rattus norvegicus 45-57 12218049-6 2002 Inhibition of EGF receptor tyrosine phosphorylation, but not of the NGF receptor, reduces cAMP-induced neurite outgrowth. Tyrosine 27-35 epidermal growth factor receptor Rattus norvegicus 14-26 12189189-9 2002 Tyrosine-phosphorylated EGFR, as measured by immunoprecipitation/immunoblotting was also increased, but when normalized to total receptors, there was no net effect. Tyrosine 0-8 epidermal growth factor receptor Rattus norvegicus 24-28 12589790-3 2003 Chemical inhibition of PKA suppressed forskolin-induced EGFR tyrosine phosphorylation and ERK1/2 activation in PC12 cells. Tyrosine 61-69 epidermal growth factor receptor Rattus norvegicus 56-60 12589790-5 2003 Forskolin-induced EGFR tyrosine phosphorylation was also observed in A431 cells and in membranes isolated from these cells. Tyrosine 23-31 epidermal growth factor receptor Rattus norvegicus 18-22 12589790-1 2003 An increase in the intracellular cAMP concentration induces tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) followed by activation of extracellular signal-regulated kinases 1/2 (ERK1/2). Tyrosine 60-68 epidermal growth factor receptor Rattus norvegicus 92-124 12589790-6 2003 Phosphoamino acid analysis indicated that the recombinant catalytic subunit of PKA elicited phosphorylation of the EGFR on both tyrosine and serine but not threonine residues in A431 membranes. Tyrosine 128-136 epidermal growth factor receptor Rattus norvegicus 115-119 12589790-8 2003 While PKA may directly phosphorylate the EGFR on serine residues, PKA-induced tyrosine phosphorylation of the EGFR occurs by an indirect mechanism. Tyrosine 78-86 epidermal growth factor receptor Rattus norvegicus 110-114 12589790-1 2003 An increase in the intracellular cAMP concentration induces tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) followed by activation of extracellular signal-regulated kinases 1/2 (ERK1/2). Tyrosine 60-68 epidermal growth factor receptor Rattus norvegicus 126-130 11691539-12 2001 4-Aminopyridine induced tyrosine phosphorylation of Pyk2 and EGFR, which peaked at 5 and 10 min, respectively. Tyrosine 24-32 epidermal growth factor receptor Rattus norvegicus 61-65 11779153-4 2002 We report that the epidermal growth factor receptor (EGFR) kinase inhibitor PKI166 blocked both basal and ligand-induced tyrosine phosphorylation of the EGFR (IC(50) = 60 nM), but not of the insulin receptor or c-met. Tyrosine 121-129 epidermal growth factor receptor Rattus norvegicus 19-51 11779153-4 2002 We report that the epidermal growth factor receptor (EGFR) kinase inhibitor PKI166 blocked both basal and ligand-induced tyrosine phosphorylation of the EGFR (IC(50) = 60 nM), but not of the insulin receptor or c-met. Tyrosine 121-129 epidermal growth factor receptor Rattus norvegicus 53-57 11779153-4 2002 We report that the epidermal growth factor receptor (EGFR) kinase inhibitor PKI166 blocked both basal and ligand-induced tyrosine phosphorylation of the EGFR (IC(50) = 60 nM), but not of the insulin receptor or c-met. Tyrosine 121-129 epidermal growth factor receptor Rattus norvegicus 153-157 11907028-1 2002 Binding of ouabain to Na(+)/K(+)-ATPase activates tyrosine phosphorylation of the epidermal growth factor receptor (EGFR), Src, and p42/44 mitogen-activated protein kinases (MAPKs) in both cardiac myocytes and A7r5 cells. Tyrosine 50-58 epidermal growth factor receptor Rattus norvegicus 82-114 11907028-1 2002 Binding of ouabain to Na(+)/K(+)-ATPase activates tyrosine phosphorylation of the epidermal growth factor receptor (EGFR), Src, and p42/44 mitogen-activated protein kinases (MAPKs) in both cardiac myocytes and A7r5 cells. Tyrosine 50-58 epidermal growth factor receptor Rattus norvegicus 116-120 11408261-4 2001 The extent of EGFR tyrosine phosphorylation, a measure of EGFR activation, was substantially higher (300--350%) in the gastric and colonic mucosa of 23- (aged) vs. 4-mo-old (young) Fischer 344 rats. Tyrosine 19-27 epidermal growth factor receptor Rattus norvegicus 14-18 11533228-3 2001 Transactivation of the EGFR, defined by receptor tyrosine phosphorylation, occurred with the same time course as PDGFbetaR activation. Tyrosine 49-57 epidermal growth factor receptor Rattus norvegicus 23-27 11408261-4 2001 The extent of EGFR tyrosine phosphorylation, a measure of EGFR activation, was substantially higher (300--350%) in the gastric and colonic mucosa of 23- (aged) vs. 4-mo-old (young) Fischer 344 rats. Tyrosine 19-27 epidermal growth factor receptor Rattus norvegicus 58-62 11309236-5 2001 We found that thrombin induced EGF receptor tyrosine phosphorylation (transactivation) in A10 cells, a clonal VSMC cell line. Tyrosine 44-52 epidermal growth factor receptor Rattus norvegicus 31-43 11346883-3 2001 H(2)O(2) can directly induce tyrosine phosphorylation of epidermal growth factor receptor (EGFR). Tyrosine 29-37 epidermal growth factor receptor Rattus norvegicus 57-89 11133506-4 2001 In the airway epithelial cell line NCI-H292, exposure to cigarette smoke upregulated the EGFR mRNA expression and induced activation of EGFR-specific tyrosine phosphorylation, resulting in upregulation of MUC5AC mRNA and protein production, effects that were inhibited completely by selective EGFR tyrosine kinase inhibitors (BIBX1522, AG-1478) and that were decreased by antioxidants. Tyrosine 150-158 epidermal growth factor receptor Rattus norvegicus 136-140 11162525-4 2001 Treatment with a combination of HGF and EGF, in comparison with that of either HGF or EGF, induced tyrosine phosphorylation of both c-Met and EGF receptor (EGFR) independently and additively stimulated MAPK activity and cyclin D1 expression, resulting in additive stimulation of DNA synthesis. Tyrosine 99-107 epidermal growth factor receptor Rattus norvegicus 142-154 11162525-4 2001 Treatment with a combination of HGF and EGF, in comparison with that of either HGF or EGF, induced tyrosine phosphorylation of both c-Met and EGF receptor (EGFR) independently and additively stimulated MAPK activity and cyclin D1 expression, resulting in additive stimulation of DNA synthesis. Tyrosine 99-107 epidermal growth factor receptor Rattus norvegicus 156-160 11346883-3 2001 H(2)O(2) can directly induce tyrosine phosphorylation of epidermal growth factor receptor (EGFR). Tyrosine 29-37 epidermal growth factor receptor Rattus norvegicus 91-95 11133506-4 2001 In the airway epithelial cell line NCI-H292, exposure to cigarette smoke upregulated the EGFR mRNA expression and induced activation of EGFR-specific tyrosine phosphorylation, resulting in upregulation of MUC5AC mRNA and protein production, effects that were inhibited completely by selective EGFR tyrosine kinase inhibitors (BIBX1522, AG-1478) and that were decreased by antioxidants. Tyrosine 150-158 epidermal growth factor receptor Rattus norvegicus 136-140 10797308-3 2000 Cpd 5 induced a cellular response program that included the induction of EGFR tyrosine phosphorylation and the activation of the mitogen-activated protein kinase (MAPK) cascade. Tyrosine 78-86 epidermal growth factor receptor Rattus norvegicus 73-77 11208719-6 2001 Tyrosine phosphorylation of EGFR was determined by immunoprecipitation and Western blotting with an antiphosphotyrosine antibody. Tyrosine 0-8 epidermal growth factor receptor Rattus norvegicus 28-32 11208719-9 2001 RESULTS: Oxidative stress and osmotic stress induced tyrosine phosphorylation of EGFR within 2 minutes, followed by a marked increase in HB-EGF and amphiregulin transcripts in RGM1 cells. Tyrosine 53-61 epidermal growth factor receptor Rattus norvegicus 81-85 11208719-10 2001 Introduction of HERCD533 into the cells inhibited not only tyrosine phosphorylation of EGFR but also growth response to EGF. Tyrosine 59-67 epidermal growth factor receptor Rattus norvegicus 87-91 10976912-1 2000 TRH has been found to stimulate tyrosine phosphorylation of the epidermal growth factor (EGF) receptor. Tyrosine 32-40 epidermal growth factor receptor Rattus norvegicus 64-102 10976912-2 2000 A specific EGF receptor kinase inhibitor, tyrphostin AG1478, substantially reduced TRH-stimulated tyrosine phosphorylation of the EGF receptor. Tyrosine 98-106 epidermal growth factor receptor Rattus norvegicus 11-23 10976912-2 2000 A specific EGF receptor kinase inhibitor, tyrphostin AG1478, substantially reduced TRH-stimulated tyrosine phosphorylation of the EGF receptor. Tyrosine 98-106 epidermal growth factor receptor Rattus norvegicus 130-142 10976912-6 2000 TRH-induced tyrosine phosphorylation of the EGF receptor was reduced by incubation with a protein kinase C (PKC) kinase inhibitor, GF109203X. Tyrosine 12-20 epidermal growth factor receptor Rattus norvegicus 44-56 10797308-8 2000 Cpd 5-altered cells had a decreased ability to dephosphorylate tyrosine phosphorylated EGFR, providing evidence for an inhibition of tyrosine phosphatase activity. Tyrosine 63-71 epidermal growth factor receptor Rattus norvegicus 87-91 10797308-4 2000 EGFR tyrosine phosphorylation was induced by Cpd 5 in a time- and dose-dependent manner. Tyrosine 5-13 epidermal growth factor receptor Rattus norvegicus 0-4 10797308-5 2000 Coimmunoprecipitation studies demonstrated that both EGF and Cpd 5 induced tyrosine phosphorylation of EGFR was associated with increased amounts of adapter proteins Shc and Grb2, and the Ras GTP-GDP exchange protein Sos, indicating the formation of functional EGFR complexes. Tyrosine 75-83 epidermal growth factor receptor Rattus norvegicus 103-107 10797308-5 2000 Coimmunoprecipitation studies demonstrated that both EGF and Cpd 5 induced tyrosine phosphorylation of EGFR was associated with increased amounts of adapter proteins Shc and Grb2, and the Ras GTP-GDP exchange protein Sos, indicating the formation of functional EGFR complexes. Tyrosine 75-83 epidermal growth factor receptor Rattus norvegicus 261-265 10900465-8 2000 EGFR tyrosine phosphorylation and downstream signaling lasted 6 h in control cells versus 2 h in AAF-exposed hepatocytes. Tyrosine 5-13 epidermal growth factor receptor Rattus norvegicus 0-4 10798649-11 2000 Immunoprecipitation showed that EGFR was phosphorylated on tyrosine residues within 30 minutes after wounding and that phosphorylation levels increased after wounding. Tyrosine 59-67 epidermal growth factor receptor Rattus norvegicus 32-36 10783131-8 2000 V(2)O(5) strongly tyrosine-phosphorylated a 115-kD protein (p115) and activation of p115 was inhibited 60 to 70% by AG1478, indicating that this protein was an EGF-R substrate. Tyrosine 18-26 epidermal growth factor receptor Rattus norvegicus 160-165 10783131-12 2000 These data suggest that V(2)O(5) activation of ERK-1/2 is oxidant-dependent and mediated through tyrosine phosphorylation of EGF-R and an EGF-R substrate which we identified as a 115-kD SH-PTP2-binding protein. Tyrosine 97-105 epidermal growth factor receptor Rattus norvegicus 125-130 10900465-6 2000 The initial tyrosine phosphorylation of EGFR and downstream activation of Sos, Raf-1, and extracellular signal-regulated protein kinase (ERK) were similar in AAF-treated and control hepatocytes. Tyrosine 12-20 epidermal growth factor receptor Rattus norvegicus 40-44 10666084-3 2000 The stretch rapidly (within 2 min) induced tyrosine phosphorylation of several proteins, among which 180-kDa protein was shown to be EGFR as revealed by blockade with AG-1478 as well as immunoprecipitation with anti-EGFR antibody coupled with immunoblotting with anti-phosphotyrosine antibody. Tyrosine 43-51 epidermal growth factor receptor Rattus norvegicus 133-137 10795716-6 2000 Likewise, EGFR and Shc, an adaptor protein that plays a crucial role in linking EGFR to Ras activation, underwent tyrosine phosphorylation to a similar degree in both young and aged hepatocytes. Tyrosine 114-122 epidermal growth factor receptor Rattus norvegicus 10-14 10666084-3 2000 The stretch rapidly (within 2 min) induced tyrosine phosphorylation of several proteins, among which 180-kDa protein was shown to be EGFR as revealed by blockade with AG-1478 as well as immunoprecipitation with anti-EGFR antibody coupled with immunoblotting with anti-phosphotyrosine antibody. Tyrosine 43-51 epidermal growth factor receptor Rattus norvegicus 216-220 10666084-4 2000 The stretch rapidly (within 2 min) induced association of tyrosine-phosphorylated EGFR with adaptor proteins (Shc/Grb2) as revealed by coprecipitation with glutathione-S-transferase-Grb2 fusion protein coupled with immunoblotting with anti-phosphotyrosine, anti-EGFR, and anti-Shc antibodies. Tyrosine 58-66 epidermal growth factor receptor Rattus norvegicus 82-86 10666084-4 2000 The stretch rapidly (within 2 min) induced association of tyrosine-phosphorylated EGFR with adaptor proteins (Shc/Grb2) as revealed by coprecipitation with glutathione-S-transferase-Grb2 fusion protein coupled with immunoblotting with anti-phosphotyrosine, anti-EGFR, and anti-Shc antibodies. Tyrosine 58-66 epidermal growth factor receptor Rattus norvegicus 262-266 10559235-8 1999 In vitro phosphorylation assays showed that PDGF receptor, calcium-dependent tyrosine kinase (CADTK/Pyk-2), Src kinase, and epidermal growth factor receptor all were able to phosphorylate purified annexin VII and XI on tyrosine residues. Tyrosine 77-85 epidermal growth factor receptor Rattus norvegicus 124-156 10559264-8 1999 The cathepsin-B proinhibitor CA074-Me inhibited both in vivo and in vitro the endosomal degradation of the EGFR and increased the tyrosine phosphorylation states of the EGFR protein and the molecule SHC within endosomes. Tyrosine 130-138 epidermal growth factor receptor Rattus norvegicus 169-173 10561490-6 1999 A massive translocation of the EGFR to the endosomal compartment was observed in response to ligand injection coincident with its tyrosine phosphorylation and receptor recruitment of the tyrosine-phosphorylated adaptor protein Shc. Tyrosine 130-138 epidermal growth factor receptor Rattus norvegicus 31-35 10561490-6 1999 A massive translocation of the EGFR to the endosomal compartment was observed in response to ligand injection coincident with its tyrosine phosphorylation and receptor recruitment of the tyrosine-phosphorylated adaptor protein Shc. Tyrosine 187-195 epidermal growth factor receptor Rattus norvegicus 31-35 10092515-4 1999 In cultured hepatocytes from control rats, EGF rapidly induced tyrosine phosphorylation of both the EGFR and of PLC-gamma1. Tyrosine 63-71 epidermal growth factor receptor Rattus norvegicus 100-104 10356362-5 1999 MAPK was present in wheat-germ agglutinin (WGA) eluates prepared from ENs and was maximally tyrosine-phosphorylated at the time peak of EGFR internalization. Tyrosine 92-100 epidermal growth factor receptor Rattus norvegicus 136-140 10377066-7 1999 Tyrosine-phosphorylated EGF-R (pEGF-R), the bioactive form, was also highest on Days 10 and 12. Tyrosine 0-8 epidermal growth factor receptor Rattus norvegicus 24-29 10401681-8 1999 Under these conditions epidermal growth factor (EGF) receptor tyrosine phosphorylation was also studied. Tyrosine 62-70 epidermal growth factor receptor Rattus norvegicus 23-61 10206334-0 1999 Possible regulation of epidermal growth factor-receptor tyrosine autophosphorylation by calcium and G proteins in chemically permeabilized rat UMR106 cells. Tyrosine 56-64 epidermal growth factor receptor Rattus norvegicus 23-55 10206334-6 1999 Adding Ca2+ (< or = 10(-6) M), with or without exogenous MgATP, dose-dependently attenuated EGF-induced tyrosine phosphorylation of EGF receptors (EGFR) and other substrates in UMR106 cells, but was less effective in A431 cells. Tyrosine 107-115 epidermal growth factor receptor Rattus norvegicus 135-148 10206334-13 1999 These results strongly suggest that there is crosstalk between EGFR-activated tyrosine phosphorylation/dephosphorylation pathways and both Ca2+- and G protein-mediated pathways in UMR106 cells, revealing a previously unrecognized modulation of EGF signalling in osteoblast-like cells that contrasts with the simpler regulatory mechanisms found in A431 cells. Tyrosine 78-86 epidermal growth factor receptor Rattus norvegicus 63-67 9426392-4 1997 A rapid (< 1 minute) and specific tyrosine phosphorylation of beta-catenin and epidermal growth factor receptor was detected in cells treated with recombinant rat TFF3. Tyrosine 37-45 epidermal growth factor receptor Rattus norvegicus 82-114 9890893-7 1999 The entire protein was phosphorylated by rEGFR at eight tyrosine residues (Y285, Y373, Y406, Y447, Y472, Y619, Y657, and Y689). Tyrosine 56-64 epidermal growth factor receptor Rattus norvegicus 41-46 9892141-7 1999 The pathway from the EGF-R involves protein tyrosine phosphorylation initiated by AT1 receptors. Tyrosine 44-52 epidermal growth factor receptor Rattus norvegicus 21-26 9722539-7 1998 Down-regulation of PKC and inhibition of the elevation of [Ca2+]i, conditions that block the activation of MAP kinase, also blocked the increases in the tyrosine phosphorylation of RAFTK and the EGF receptor. Tyrosine 153-161 epidermal growth factor receptor Rattus norvegicus 195-207 9722539-8 1998 AG1478, a tyrphostin selective for the EGF receptor, reduced the activation of MAP kinase, the tyrosine phosphorylation of SHC, the association of Grb2 with SHC, and the tyrosine phosphorylation of the EGF receptor and p120(cbl) but did not block the tyrosine phosphorylation of RAFTK. Tyrosine 95-103 epidermal growth factor receptor Rattus norvegicus 39-51 9722539-8 1998 AG1478, a tyrphostin selective for the EGF receptor, reduced the activation of MAP kinase, the tyrosine phosphorylation of SHC, the association of Grb2 with SHC, and the tyrosine phosphorylation of the EGF receptor and p120(cbl) but did not block the tyrosine phosphorylation of RAFTK. Tyrosine 170-178 epidermal growth factor receptor Rattus norvegicus 39-51 9722539-8 1998 AG1478, a tyrphostin selective for the EGF receptor, reduced the activation of MAP kinase, the tyrosine phosphorylation of SHC, the association of Grb2 with SHC, and the tyrosine phosphorylation of the EGF receptor and p120(cbl) but did not block the tyrosine phosphorylation of RAFTK. Tyrosine 170-178 epidermal growth factor receptor Rattus norvegicus 39-51 9671791-5 1998 Lysophosphatidic acid not only induces ligand-independent tyrosine autophosphorylation of EGFR but also of platelet-derived growth factor beta receptor (PDGF-beta-R) as shown by detection of tyrosine phosphorylation and by the use of specific inhibitors of RTKs. Tyrosine 58-66 epidermal growth factor receptor Rattus norvegicus 90-94 9710602-7 1998 The arsenite-induced tyrosine phosphorylation of Shc, enhancement of Shc and Grb2 interactions, and activation of ERK were all drastically reduced by treatment of cells with either the general growth factor receptor poison suramin or the EGFR-selective inhibitor tyrphostin AG1478. Tyrosine 21-29 epidermal growth factor receptor Rattus norvegicus 238-242 9710602-8 1998 Down-regulation of EGFR expression through pretreatment of cells with EGF also attenuated ERK activation and Shc tyrosine phosphorylation in response to arsenite treatment. Tyrosine 113-121 epidermal growth factor receptor Rattus norvegicus 19-23 9662041-8 1998 Betacellulin induced the tyrosine phosphorylation of ErbB-1, ErbB-2 and ErbB-4. Tyrosine 25-33 epidermal growth factor receptor Rattus norvegicus 53-59 9600380-4 1998 EGFR was studied using three different antibodies which were found to stain for a tyrosine-phosphorylated protein (p170) corresponding to the membrane-anchored EGFR. Tyrosine 82-90 epidermal growth factor receptor Rattus norvegicus 0-4 9600380-4 1998 EGFR was studied using three different antibodies which were found to stain for a tyrosine-phosphorylated protein (p170) corresponding to the membrane-anchored EGFR. Tyrosine 82-90 epidermal growth factor receptor Rattus norvegicus 160-164 9535870-2 1998 In the present study, we found Ang II rapidly induced the tyrosine phosphorylation of the epidermal growth factor (EGF) receptor and its association with Shc and Grb2. Tyrosine 58-66 epidermal growth factor receptor Rattus norvegicus 90-128 9384582-4 1997 The increase in SHC tyrosine phosphorylation and MAPK stimulation through both Gq- and Gi-coupled receptors was reduced strongly upon selective inhibition of EGFR function. Tyrosine 20-28 epidermal growth factor receptor Rattus norvegicus 158-162 9384582-6 1997 Furthermore, the Src tyrosine kinase inhibitor PP1 strongly interfered with LPA- and EGF-induced tyrosine phosphorylation and MAPK activation downstream of EGFR. Tyrosine 21-29 epidermal growth factor receptor Rattus norvegicus 156-160 9312072-2 1997 Here we demonstrate that both depolarization-induced calcium influx and treatment with bradykinin stimulate tyrosine phosphorylation of the epidermal growth factor receptor (EGFR). Tyrosine 108-116 epidermal growth factor receptor Rattus norvegicus 140-172 9312072-2 1997 Here we demonstrate that both depolarization-induced calcium influx and treatment with bradykinin stimulate tyrosine phosphorylation of the epidermal growth factor receptor (EGFR). Tyrosine 108-116 epidermal growth factor receptor Rattus norvegicus 174-178 9312072-4 1997 Furthermore, bradykinin-stimulated EGFR transactivation is critically dependent on the presence of extracellular calcium, and when triggered by ionophore treatment, calcium influx is already sufficient to induce EGFR tyrosine phosphorylation. Tyrosine 217-225 epidermal growth factor receptor Rattus norvegicus 35-39 9110995-2 1997 This process is characterized by a progressive decrease in epidermal growth factor (EGF) receptor level measured by 125I-EGF binding, tyrosine phosphorylation, and Western blotting. Tyrosine 134-142 epidermal growth factor receptor Rattus norvegicus 59-97 9312072-4 1997 Furthermore, bradykinin-stimulated EGFR transactivation is critically dependent on the presence of extracellular calcium, and when triggered by ionophore treatment, calcium influx is already sufficient to induce EGFR tyrosine phosphorylation. Tyrosine 217-225 epidermal growth factor receptor Rattus norvegicus 212-216 9207933-5 1997 The distribution of EGFR and tyrosine-phosphorylated EGFR was regulated by cell density. Tyrosine 29-37 epidermal growth factor receptor Rattus norvegicus 53-57 9207933-6 1997 At confluence, EGFR and tyrosine-phosphorylated EGFR were predominantly associated with the Triton X-100-insoluble CSK at confluence, while predominantly Triton X-100-soluble at subconfluence. Tyrosine 24-32 epidermal growth factor receptor Rattus norvegicus 48-52 9178701-4 1997 Tyrosine phosphorylation of EGF receptor (EGFR), Shc, and phospholipase-C gamma1 (PLC gamma), and growth factor receptor binding protein 2 (Grb2) coprecipitation with EGFR and Shc were analyzed by Western blotting. Tyrosine 0-8 epidermal growth factor receptor Rattus norvegicus 28-40 9178701-4 1997 Tyrosine phosphorylation of EGF receptor (EGFR), Shc, and phospholipase-C gamma1 (PLC gamma), and growth factor receptor binding protein 2 (Grb2) coprecipitation with EGFR and Shc were analyzed by Western blotting. Tyrosine 0-8 epidermal growth factor receptor Rattus norvegicus 42-46 9178701-4 1997 Tyrosine phosphorylation of EGF receptor (EGFR), Shc, and phospholipase-C gamma1 (PLC gamma), and growth factor receptor binding protein 2 (Grb2) coprecipitation with EGFR and Shc were analyzed by Western blotting. Tyrosine 0-8 epidermal growth factor receptor Rattus norvegicus 167-171 9016808-7 1997 The EGF-induced effect on deoxynucleic acid synthesis was inhibited by transforming growth factor-beta and tyrphostin, a tyrosine kinase inhibitor that blocks the phosphorylation of tyrosine residues on EGF-R. Tyrosine 121-129 epidermal growth factor receptor Rattus norvegicus 203-208 9067479-6 1997 Western blot analysis, using anti-tyrosine phosphorylated epidermal growth factor receptor (active form) antibody, revealed a major immunoreactive protein band (180 kDa) in all samples pre-incubated with 1 microM epidermal growth factor. Tyrosine 34-42 epidermal growth factor receptor Rattus norvegicus 58-90 9202672-7 1997 EGFr tyrosine phosphorylation was determined by immunoprecipitating the EGFr and immunoblotting with an antibody against phosphotyrosine. Tyrosine 5-13 epidermal growth factor receptor Rattus norvegicus 0-4 9202672-7 1997 EGFr tyrosine phosphorylation was determined by immunoprecipitating the EGFr and immunoblotting with an antibody against phosphotyrosine. Tyrosine 5-13 epidermal growth factor receptor Rattus norvegicus 72-76 8596637-3 1996 We report here that the epidermal growth factor receptor (EGFR) and the neu oncoprotein become rapidly tyrosine-phosphorylated upon stimulation of Rat-1 cells with the GPCR agonists endothelin-1, lysophosphatic acid and thrombin, suggesting that there is an intracellular mechanism for transactivation. Tyrosine 103-111 epidermal growth factor receptor Rattus norvegicus 24-56 8765213-8 1996 These changes were accompanied by parallel alterations in the number of proliferating cell nuclear antigen-immunoreactive cells and the Tyr-k activity of EGF-R. Tyrosine 136-139 epidermal growth factor receptor Rattus norvegicus 154-159 8765213-10 1996 In these animals, the Tyr-k activity of EGF-R was also decreased by 30%. Tyrosine 22-25 epidermal growth factor receptor Rattus norvegicus 40-45 8596637-3 1996 We report here that the epidermal growth factor receptor (EGFR) and the neu oncoprotein become rapidly tyrosine-phosphorylated upon stimulation of Rat-1 cells with the GPCR agonists endothelin-1, lysophosphatic acid and thrombin, suggesting that there is an intracellular mechanism for transactivation. Tyrosine 103-111 epidermal growth factor receptor Rattus norvegicus 58-62 8779993-8 1996 Pretreatment with suramin, which binds to growth factor, results in increased EGFR tyrosine phosphorylation after stimulation, suggesting disruption of normal autocrine receptor downregulation. Tyrosine 83-91 epidermal growth factor receptor Rattus norvegicus 78-82 7798194-3 1994 We cloned a fragment of Shc when screening a bacterial expression library with tyrosine-phosphorylated epidermal growth factor (EGF) receptor. Tyrosine 79-87 epidermal growth factor receptor Rattus norvegicus 103-141 8625444-7 1996 We conclude that increased ligand-induced activation of EGFR Tyr-k may be an important event for development of the hyperproliferative state associated with induction of colorectal neoplasia. Tyrosine 61-64 epidermal growth factor receptor Rattus norvegicus 56-60 7541245-11 1995 We suggest that (a) activation of intrinsic Tyr-k of EGF-R is an important event in AOM induction of colonic mucosal proliferative processes, and (b) this activation is thought to be mediated by TGF-alpha through an autocrine mechanism. Tyrosine 44-47 epidermal growth factor receptor Rattus norvegicus 53-58 32001948-1 2019 Dacomitinib, a second-generation tyrosine kinase inhibitor, was irreversible inhibitor forming covalent bonds with the kinase domains of EGFR and other ErbB family receptors. Tyrosine 33-41 epidermal growth factor receptor Rattus norvegicus 152-156 7693694-7 1993 Tyrosine-phosphorylated EGF receptor peptide fragments were evaluated for specific inhibition of PTP1b and PLC gamma SH2 binding to the activated receptor. Tyrosine 0-8 epidermal growth factor receptor Rattus norvegicus 24-36 7693694-8 1993 One such peptide, modeled on EGF receptor tyrosine 992, blocked the binding of both fusion proteins. Tyrosine 42-50 epidermal growth factor receptor Rattus norvegicus 29-41 8244150-4 1993 Membrane phosphorylation studies, however, showed that TAGH induced phosphorylation of tyrosine residues in the EGF receptor. Tyrosine 87-95 epidermal growth factor receptor Rattus norvegicus 112-124 1622394-5 1992 When cells were incubated in the presence of EGF, plasma membranes from isoprenaline-treated and control animals showed phosphorylation of the EGF-R tyrosine moieties and transient increases in membrane-associated phospholipase C gamma. Tyrosine 149-157 epidermal growth factor receptor Rattus norvegicus 143-148 35457136-7 2022 Dexmedetomidine-induced EGFR tyrosine and JNK phosphorylation were inhibited by rauwolscine, PP1, PP2, GM6001, and AG1478. Tyrosine 29-37 epidermal growth factor receptor Rattus norvegicus 24-28 6325268-1 1984 The 170 000 dalton hepatic epidermal growth factor (EGF) receptor is phosphorylated on serine and tyrosine residues. Tyrosine 98-106 epidermal growth factor receptor Rattus norvegicus 27-65 8092256-6 1994 Endogenous tyrosine phosphorylation of EGFR (reflecting receptor activation) was 30-fold higher in fetal kidney membranes than in adult (3- to 7-fold higher when adjusted for differences in EGF binding or EGFR protein content). Tyrosine 11-19 epidermal growth factor receptor Rattus norvegicus 39-43 8092256-6 1994 Endogenous tyrosine phosphorylation of EGFR (reflecting receptor activation) was 30-fold higher in fetal kidney membranes than in adult (3- to 7-fold higher when adjusted for differences in EGF binding or EGFR protein content). Tyrosine 11-19 epidermal growth factor receptor Rattus norvegicus 205-209 8092256-7 1994 The EGFR substrate, phospholipase C-gamma 1, was tyrosine phosphorylated in fetal kidneys but not adult, and a greater proportion was membrane-associated in fetal kidneys, consistent with activation of phospholipase C-gamma 1. Tyrosine 49-57 epidermal growth factor receptor Rattus norvegicus 4-8 8040293-3 1994 Significant and prolonged EGF-R tyrosine autophosphorylation (which reflects receptor kinase activation) was induced by EGF in GEC adherent to collagen, but EGF did not stimulate EGF-R autophosphorylation in GEC on plastic (at 37 degrees C). Tyrosine 32-40 epidermal growth factor receptor Rattus norvegicus 26-31 6294827-0 1983 Dimethyl sulfoxide stimulates tyrosine residue phosphorylation of rat liver epidermal growth factor receptor. Tyrosine 30-38 epidermal growth factor receptor Rattus norvegicus 76-108 32001948-1 2019 Dacomitinib, a second-generation tyrosine kinase inhibitor, was irreversible inhibitor forming covalent bonds with the kinase domains of EGFR and other ErbB family receptors. Tyrosine 33-41 epidermal growth factor receptor Rattus norvegicus 137-141 31664795-0 2019 PLGA Porous Microspheres Dry Powders for Codelivery of Afatinib-Loaded Solid Lipid Nanoparticles and Paclitaxel: Novel Therapy for EGFR Tyrosine Kinase Inhibitors Resistant Nonsmall Cell Lung Cancer. Tyrosine 136-144 epidermal growth factor receptor Rattus norvegicus 131-135 31664795-1 2019 Combination therapy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR TKIs) with other chemotherapeutic agents is a feasible strategy to overcome resistance that often occurs after 9-13 months of EGFR TKIs administration in nonsmall cell lung cancer (NSCLC). Tyrosine 63-71 epidermal growth factor receptor Rattus norvegicus 23-55 31664795-1 2019 Combination therapy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR TKIs) with other chemotherapeutic agents is a feasible strategy to overcome resistance that often occurs after 9-13 months of EGFR TKIs administration in nonsmall cell lung cancer (NSCLC). Tyrosine 63-71 epidermal growth factor receptor Rattus norvegicus 57-61 31664795-1 2019 Combination therapy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR TKIs) with other chemotherapeutic agents is a feasible strategy to overcome resistance that often occurs after 9-13 months of EGFR TKIs administration in nonsmall cell lung cancer (NSCLC). Tyrosine 63-71 epidermal growth factor receptor Rattus norvegicus 91-95 31664795-1 2019 Combination therapy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR TKIs) with other chemotherapeutic agents is a feasible strategy to overcome resistance that often occurs after 9-13 months of EGFR TKIs administration in nonsmall cell lung cancer (NSCLC). Tyrosine 63-71 epidermal growth factor receptor Rattus norvegicus 91-95 28294531-8 2017 These results demonstrate that tyrosine phosphorylation of BK channels by EGFR kinase decreases the channel activity, and inhibition of EGFR kinase by AG556 enhances the channel activity and dilates rat cerebral basilar arteries. Tyrosine 31-39 epidermal growth factor receptor Rattus norvegicus 74-78 30926678-5 2019 Src phosphorylates EGFR at tyrosine 845 and then transactive EGFR. Tyrosine 27-35 epidermal growth factor receptor Rattus norvegicus 19-23 29723130-7 2018 TFF3 caused tyrosine phosphorylation of EGFR in INS-1E beta-cells, and purified recombinant TFF3 increased both attachment and spreading of INS-1E beta-cells. Tyrosine 12-20 epidermal growth factor receptor Rattus norvegicus 40-44 28943431-5 2017 This sustained EGFR transactivation is mainly due to Src kinase-mediated persistent EGFR tyrosine phosphorylation at Y845 rather than Y1173. Tyrosine 89-97 epidermal growth factor receptor Rattus norvegicus 15-19 28943431-5 2017 This sustained EGFR transactivation is mainly due to Src kinase-mediated persistent EGFR tyrosine phosphorylation at Y845 rather than Y1173. Tyrosine 89-97 epidermal growth factor receptor Rattus norvegicus 84-88 26399481-2 2015 In the present study, the role of tyrosine-phosphorylated CaM [P-(Tyr)-CaM] on the regulation of the epidermal growth factor receptor (EGFR) has been examined using in vitro assay systems. Tyrosine 34-42 epidermal growth factor receptor Rattus norvegicus 101-133 26399481-7 2015 Also a CaM(Y99D/Y138D) mutant mimicked the effect of P-(Tyr)-CaM on ligand-dependent EGFR activation. Tyrosine 56-59 epidermal growth factor receptor Rattus norvegicus 85-89 26399481-2 2015 In the present study, the role of tyrosine-phosphorylated CaM [P-(Tyr)-CaM] on the regulation of the epidermal growth factor receptor (EGFR) has been examined using in vitro assay systems. Tyrosine 34-42 epidermal growth factor receptor Rattus norvegicus 135-139 26399481-2 2015 In the present study, the role of tyrosine-phosphorylated CaM [P-(Tyr)-CaM] on the regulation of the epidermal growth factor receptor (EGFR) has been examined using in vitro assay systems. Tyrosine 66-69 epidermal growth factor receptor Rattus norvegicus 101-133 26399481-2 2015 In the present study, the role of tyrosine-phosphorylated CaM [P-(Tyr)-CaM] on the regulation of the epidermal growth factor receptor (EGFR) has been examined using in vitro assay systems. Tyrosine 66-69 epidermal growth factor receptor Rattus norvegicus 135-139 26399481-3 2015 We show that phosphorylation of CaM by rat liver solubilized EGFR leads to a dramatic increase in the subsequent phosphorylation of poly-L-(Glu:Tyr) (PGT) by the receptor in the presence of ligand, both in the absence and in the presence of Ca(2+). Tyrosine 144-147 epidermal growth factor receptor Rattus norvegicus 61-65 25078264-2 2014 This process was characterized by a progressive decrease in EGFR level, as measured by (125)I-EGF binding and Scatchard analysis, tyrosine phosphorylation, Western blotting, and bio-imaging using EGF-labeled with a near-infrared probe. Tyrosine 130-138 epidermal growth factor receptor Rattus norvegicus 60-64 25548285-5 2015 Coadministration of insulin and FFAs, however, abolished hepatocyte proliferation and triggered CD95-dependent apoptosis due to a JNK-dependent association of the activated EGFR with CD95, subsequent CD95 tyrosine phosphorylation and formation of the death-inducing signaling complex (DISC). Tyrosine 205-213 epidermal growth factor receptor Rattus norvegicus 173-177 20571033-3 2010 Insulin (35 nmol/liter) induced phosphorylation of the EGFR at position Tyr(845) and Tyr(1173), but not at Tyr(1045), suggesting that EGF is not involved in insulin-induced EGFR activation. Tyrosine 72-75 epidermal growth factor receptor Rattus norvegicus 55-59 21806601-5 2012 KEY RESULTS: Diabetes significantly enhanced phosphorylation of EGF receptor at tyrosine residues Y992, Y1068, Y1086, Y1148, as well as ERK1/2 and p38 MAPK in the mesenteric vasculature bed whereas these changes were significantly attenuated upon Ang-(1-7) or AG1478 treatment. Tyrosine 80-88 epidermal growth factor receptor Rattus norvegicus 64-76 22028338-8 2012 Interestingly, tyrosine phosphorylation levels of cardiac Na(+) channels (I(Na)) and L-type Ca(2+) channels (I(Ca,L)) were significantly increased at time points corresponding to the alteration of EGFR phosphorylation levels during reperfusion. Tyrosine 15-23 epidermal growth factor receptor Rattus norvegicus 197-201 22028338-12 2012 CONCLUSION: These results demonstrate for the first time that EGFR plays an important role in the genesis of arrhythmias induced by reperfusion, which is likely mediated at least in part by enhancing tyrosine phosphorylation of cardiac Na(+) and L-type Ca(2+) channels. Tyrosine 200-208 epidermal growth factor receptor Rattus norvegicus 62-66 25505586-5 2014 OVA induced rapid increases in the phosphorylation of MYPT1 (Thr-853), Src (Tyr-416), and EGFR (Tyr-1173) in VSMCs, and Src inhibitors abolished these effects. Tyrosine 96-99 epidermal growth factor receptor Rattus norvegicus 90-94 25505586-9 2014 OVA also induced EGFR phosphorylation at Tyr-845, one of residues phosphorylated by Src. Tyrosine 41-44 epidermal growth factor receptor Rattus norvegicus 17-21 21856923-7 2011 Furthermore, the alpha(1)-AR-activated STAT3 was associated with transactivation of EGFR because inhibition of EGFR with the selective inhibitor AG1478 prevented alpha(1)-AR-induced STAT3 tyrosine phosphorylation and its transcriptional activity, as well as cardiac hypertrophy. Tyrosine 188-196 epidermal growth factor receptor Rattus norvegicus 84-88 21856923-7 2011 Furthermore, the alpha(1)-AR-activated STAT3 was associated with transactivation of EGFR because inhibition of EGFR with the selective inhibitor AG1478 prevented alpha(1)-AR-induced STAT3 tyrosine phosphorylation and its transcriptional activity, as well as cardiac hypertrophy. Tyrosine 188-196 epidermal growth factor receptor Rattus norvegicus 111-115 18330891-3 2008 We found that prothrombin treatment of rat hepatocytes without addition of any growth factor induced tyrosine phosphorylation of integrin alpha5 and interaction of integrin alpha5 with epidermal growth factor receptor (EGFR), leading to EGFR tyrosine phosphorylation at tyrosine residues Tyr-845 and Tyr-1173. Tyrosine 242-250 epidermal growth factor receptor Rattus norvegicus 219-223 19434003-9 2009 Western blot analysis revealed that ZD1839 substantially reduced tyrosine phosphorylation of ErbB1 as well as ErbB2 and ErbB3. Tyrosine 65-73 epidermal growth factor receptor Rattus norvegicus 93-98 19254952-9 2009 beta-Arrestin2 facilitates ANG and SII stimulation of Src-mediated phosphorylation of Tyr-845 on the EGFR, a known site for Src phosphorylation. Tyrosine 86-89 epidermal growth factor receptor Rattus norvegicus 101-105 18671962-5 2008 We also examined the effects of antioxidant pretreatment on urotensin II-induced cell proliferation, extracellular signal-regulated kinase phosphorylation, and the tyrosine phosphorylation of epidermal growth factor receptor, to elucidate the redox-sensitive pathway in urotensin II-induced cell proliferation. Tyrosine 164-172 epidermal growth factor receptor Rattus norvegicus 192-224 19553664-8 2009 When, however, a JNK signal was induced by coadministration of cycloheximide or hydrogen peroxide (H2O2), activated EGFR associated with CD95 and triggered EGFR-mediated CD95-tyrosine phosphorylation and subsequent formation of the death-inducing signaling complex. Tyrosine 175-183 epidermal growth factor receptor Rattus norvegicus 116-120 19553664-8 2009 When, however, a JNK signal was induced by coadministration of cycloheximide or hydrogen peroxide (H2O2), activated EGFR associated with CD95 and triggered EGFR-mediated CD95-tyrosine phosphorylation and subsequent formation of the death-inducing signaling complex. Tyrosine 175-183 epidermal growth factor receptor Rattus norvegicus 156-160 19225541-9 2009 (2) Rapid tyrosine-phosphorylation of EGFR correlated well with the onset of increased HA synthesis. Tyrosine 10-18 epidermal growth factor receptor Rattus norvegicus 38-42 19954006-7 2009 Expression of EGFR and tyrosine phosphorylation (EGFR activation) in airway epithelium at different times of OVA exposure were evaluated by immunohistochemical and immunofluorescence. Tyrosine 23-31 epidermal growth factor receptor Rattus norvegicus 49-53 19954006-18 2009 Genistein decreased tyrosine phosphorylation of EGFR in subgroups C1, C2 and C4[(3.12 +/- 0.24), (3.00 +/- 0.28), (2.69 +/- 0.54)] as compared to subgroups B1, B2 and B4[(3.69 +/- 0.43), (3.57 +/- 0.29), (4.46 +/- 0.47), respectively] (all P < 0.05). Tyrosine 20-28 epidermal growth factor receptor Rattus norvegicus 48-52 19288512-4 2009 Interestingly, following the administration of either a low or high dose of EGF, the pool of EGFR in the PM-DRM fraction became highly Tyr-phosphorylated. Tyrosine 135-138 epidermal growth factor receptor Rattus norvegicus 93-97 19288512-5 2009 In accordance with the higher level of EGFR Tyr-Phosphorylation, EGF induced an augmented recruitment of Grb2 and Shc proteins to PM-DRMs compared with whole PM. Tyrosine 44-47 epidermal growth factor receptor Rattus norvegicus 39-43 18330891-3 2008 We found that prothrombin treatment of rat hepatocytes without addition of any growth factor induced tyrosine phosphorylation of integrin alpha5 and interaction of integrin alpha5 with epidermal growth factor receptor (EGFR), leading to EGFR tyrosine phosphorylation at tyrosine residues Tyr-845 and Tyr-1173. Tyrosine 288-291 epidermal growth factor receptor Rattus norvegicus 219-223 18330891-3 2008 We found that prothrombin treatment of rat hepatocytes without addition of any growth factor induced tyrosine phosphorylation of integrin alpha5 and interaction of integrin alpha5 with epidermal growth factor receptor (EGFR), leading to EGFR tyrosine phosphorylation at tyrosine residues Tyr-845 and Tyr-1173. Tyrosine 300-303 epidermal growth factor receptor Rattus norvegicus 219-223 18330891-4 2008 EGFR tyrosine phosphorylation triggered phosphorylation of its down-stream target Shc and the activation of the c-Jun N-terminal kinase (JNK) pathway. Tyrosine 5-13 epidermal growth factor receptor Rattus norvegicus 0-4 18330891-3 2008 We found that prothrombin treatment of rat hepatocytes without addition of any growth factor induced tyrosine phosphorylation of integrin alpha5 and interaction of integrin alpha5 with epidermal growth factor receptor (EGFR), leading to EGFR tyrosine phosphorylation at tyrosine residues Tyr-845 and Tyr-1173. Tyrosine 242-250 epidermal growth factor receptor Rattus norvegicus 219-223 18216199-8 2008 Furthermore, EGF was required to observe phospho-tyrosine EGFR immunostaining of glial progenitors in culture. Tyrosine 49-57 epidermal growth factor receptor Rattus norvegicus 58-62 18295415-9 2008 HCB induced the association of the EGFR with c-Src and increased the phosphorylation of EGFR at tyrosine 845 (Tyr845), a known c-Src phosphorylation site. Tyrosine 96-104 epidermal growth factor receptor Rattus norvegicus 88-92 17908994-11 2007 A strong inhibition of total and phosphorylated form of EGFR (Tyr(992) and Tyr(845)) and Akt (Ser(473)) was significant in rats given with these agents in combination. Tyrosine 62-65 epidermal growth factor receptor Rattus norvegicus 56-60 17678888-6 2007 Leptin induced significant tyrosine phosphorylation of epidermal growth factor receptor, which was significantly attenuated by two inhibitors, an epidermal growth factor receptor tyrosine kinase inhibitor, AG1478, and a broad-spectrum matrix metalloproteinase inhibitor, GM6001. Tyrosine 27-35 epidermal growth factor receptor Rattus norvegicus 55-87 17678888-6 2007 Leptin induced significant tyrosine phosphorylation of epidermal growth factor receptor, which was significantly attenuated by two inhibitors, an epidermal growth factor receptor tyrosine kinase inhibitor, AG1478, and a broad-spectrum matrix metalloproteinase inhibitor, GM6001. Tyrosine 27-35 epidermal growth factor receptor Rattus norvegicus 146-178 17258167-4 2007 The NADPH oxidase-derived ROS signal then allows via Yes, JNK, and EGFR activation for CD95 tyrosine phosphorylation as a prerequisite for CD95 targeting to the plasma membrane and formation of the death inducing signalling complex. Tyrosine 92-100 epidermal growth factor receptor Rattus norvegicus 67-71 17307332-6 2007 Transfection of siRNAs targeting PKCalpha also enhanced bombesin-induced EGFR tyrosine phosphorylation in Rat-1 cells. Tyrosine 78-86 epidermal growth factor receptor Rattus norvegicus 73-77 17363458-2 2007 Both of these techniques show that after EGF administration, a distinctive population of intracellular EGFR, which was characterized by a high level of tyrosine phosphorylation, accumulated in endosomes. Tyrosine 152-160 epidermal growth factor receptor Rattus norvegicus 103-107 17363458-3 2007 EGFR recruited to early endosomes were more tyrosine phosphorylated than those from late endosomes. Tyrosine 44-52 epidermal growth factor receptor Rattus norvegicus 0-4 17363458-4 2007 However, the level of tyrosine phosphorylation of EGFR in DRMs isolated from early and late endosomes was comparable, suggesting that EGFR in endosomal DRMs are more resistant to tyrosine dephosphorylation. Tyrosine 22-30 epidermal growth factor receptor Rattus norvegicus 50-54 17372590-7 2007 Curcumin interrupts PDGF and EGF signaling demonstrated by inhibiting tyrosine phosphorylation of PDGF-betaR and EGFR and by reducing the levels of phosphorylated phosphatidylinositol-3 kinase (PI-3K/AKT), extracellular signal-regulated kinase (ERK) and the Jun N-terminal kinase (JNK). Tyrosine 70-78 epidermal growth factor receptor Rattus norvegicus 113-117